AI-generated · cited to primary sources · not investment advice
Cipla (500087) May 2025 Filing Analysis
How durable is the business?
Cipla is aggressively expanding its complex generic pipeline, specifically in peptides and respiratory assets, to offset the eventual revenue compression from generic Revlimid. (3 expanding)
“In respiratory, we have filed 6 assets... In peptides and complex generics, 9 assets are already filed and some launches projected between FY '26 and '28.”
See the full cited Business Model analysis of Cipla
Where does growth come from?
Cipla has successfully navigated US FDA inspections across five key manufacturing sites in FY25, all receiving 'VAI' (Voluntary Action Indicated) status. This compliance stability is a critical prerequisite for their expansion and new product launch plans in North America. (1 steady across 1 signal)
“5 Manufacturing facilities were audited by the USFDA in FY25. All 5 inspections have been classified as ‘VAI’”
See the full cited Future Growth analysis of Cipla
What could break the thesis?
The risk is intensifying as management explicitly guides for a 'compression' in Revlimid (lenalidomide) revenue over the next 2-3 quarters as it loses exclusivity, which will drag down overall margins. (1 intensifying)
“But you also have to see the next 2 or 3 quarters is when we will see a compression in lena. And that will be offset by these new products that are coming up.”
The regulatory risk profile for Indian facilities is easing significantly as 5 major Indian sites (Patalganga, Kurkumbh, Goa, Virgonagar, Medispray) were recently classified as VAI (Voluntary Action Indicated), meaning they are in good standing. (3 easing, 1 stable)
“the U.S. FDA audited 5 of our manufacturing facilities based in India... and all of these inspections have been classified as VAI.”
Margins have significantly improved and stabilized. FY25 EBITDA margin reached 25.9% (up 139 bps YoY), far exceeding the previous guidance of 21%. (1 easing)
“EBITDA % 25.9% 139 bps (vs FY24); PAT % 19.1% 301 bps (vs FY24)”
The risk is easing as management reports that supplies have resumed, volumes in Q4 were significantly higher than Q3, and the product is returning to 'normalcy' in the US channel. (4 easing)
“I think on Lanreotide, as I mentioned, this quarter is -- the quarter that went by, quarter 4, was significantly higher than quarter 3 and -- in terms of volume. And also this quarter, we are coming back to normalcy.”
See the full cited Risk analysis of Cipla
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.